Al-Banaa, Kadhim and Gallastegui-Crestani, Nicolas and von Drygalski, Annette (2021) Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A. European Journal of Case Reports in Internal Medicine, 8 (11). pp. 1-5. ISSN 2284-2594
|
Text
2984-Article Text-25447-1-10-20211110.pdf - Published Version Download (454kB) | Preview |
Abstract
Acquired haemophilia A (AHA) is a rare haemorrhagic disorder caused by the development of autoantibodies inhibiting factor VIII function. It predominantly affects the elderly, who are often burdened with a considerable number of comorbidities, and can result in life-threatening bleeding. The management of AHA consists of two aspects: inhibitor eradication with an immunomodulator and bleed control with a bypassing agent.Here we present a case of AHA with a high titre inhibitor in a patient with extensive comorbidities and atrial fibrillation in whom inhibitor eradication could not be achieved within a few weeks using corticosteroids alone. Due to coronavirus disease (COVID)-19 restrictions and complications of care, emicizumab offered an effective and convenient therapy, not only sparing the need for continued and intensified inhibitor eradication, but also allowing anticoagulation for stroke prophylaxis.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Acquired haemophilia A, haemorrhage, emicizumab, anticoagulation, venous thromboembolism, atrial fibrillation |
| Subjects: | 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) |
| Depositing User: | Marina Spanti |
| Date Deposited: | 21 Feb 2022 12:56 |
| Last Modified: | 21 Feb 2022 12:56 |
| URI: | http://eprints.bice.rm.cnr.it/id/eprint/21747 |
Actions (login required)
 |
View Item |
